⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30327129 | 1.00 | — | — | |
| SCHEMBL27973278 | 0.78 | HSP90AA1 (0.37) | — | |
| SCHEMBL20312288 | 0.75 | — | — | |
| SCHEMBL4716676 | 0.73 | HSP90AA1 (0.33) | — | |
| SCHEMBL201627 | 0.72 | — | — | |
| SCHEMBL29462398 | 0.72 | — | — | |
| SCHEMBL20312326 | 0.71 | HSP90AA1 (0.39) | — | |
| Water SCHEMBL30010184 | 0.70 | LMNA (0.42) | — | |
| SCHEMBL9109465 | 0.70 | LMNA (0.42) | — | |
| SCHEMBL20312290 | 0.70 | HSP90AA1 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119674208-A | PEO-PAN-based polymer electrolyte membrane and preparation method and application thereof | 山东创鲁先进电池科技有限公司 | 2025-03-21 | — | — | CN | claimed |
| CN-119674208-A | PEO-PAN-based polymer electrolyte membrane and preparation method and application thereof | 山东创鲁先进电池科技有限公司 | 2025-03-21 | — | — | CN | disclosed |
| CN-118894861-A | Novel tricyclic compounds as IRAK4 inhibitors | 韩国化学研究院 | 2024-11-05 | — | — | CN | disclosed |
| CN-113227095-B | Novel tricyclic compounds as IRAK4 inhibitors | 韩国化学研究院 | 2024-07-05 | — | — | CN | disclosed |
| WO-2024144192-A1 | ORGANIC COMPOUND AND ORGANIC ELECTROLUMINESCENT DIODE USING SAME | 솔루스첨단소재 주식회사 | 2024-07-04 | — | — | WO | disclosed |
| CN-115636819-A | Luminescent material, application thereof and organic electroluminescent device comprising luminescent material | 清华大学 | 2023-01-24 | — | — | CN | disclosed |
| CN-113200983-B | Compound with pyrrolopyridine structure, preparation method and medical application | 中国药科大学 | 2023-01-03 | — | — | CN | disclosed |
| US-11495748-B2 | Organic compound having adamantyl fluorene ligands on 1,3,5-triazine and electronic device | SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD. (CN) | 2022-11-08 | — | — | US | disclosed |
| US-11495748-B2 | Organic compound having adamantyl fluorene ligands on 1,3,5-triazine and electronic device | SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD. (CN) | 2022-11-08 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-20090162319-A1 | REVERSE TRANSCRIPTASE INHIBITORS | ARDEA BIOSCIENCES (US) | 2009-06-25 | — | — | US | disclosed |
| WO-2009057827-A1 | PYRIDAZINONE DERIVATIVES AND USE THEREOF AS P2X7 RECEPTOR INHIBITORS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-05-07 | — | — | WO | disclosed |
| EP-1937663-A1 | THIOPHENE DERIVATIVES AS PPAR AGONISTS I | Inpharmatica Limited (GB) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007036730-A9 | THIOPHENE DERIVATIVES AS PPAR AGONISTS I | INPHARMATICA LTD (GB) | 2008-06-19 | — | — | WO | disclosed |
| WO-2007036730-A1 | THIOPHENE DERIVATIVES AS PPAR AGONISTS I | INPHARMATICA LIMITED (GB) | 2007-04-05 | — | — | WO | disclosed |
| CN-1913898-A | Substituted piperazines | CHEMOCENTRYX INC (US) | 2007-02-14 | — | — | CN | disclosed |
| EP-1691810-A1 | SUBSTITUTED PIPERAZINES | ChemoCentryx Inc (US) | 2006-08-23 | — | — | EP | disclosed |
| US-20060106218-A1 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2006-05-18 | — | — | US | disclosed |
| US-20050256130-A1 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2005-11-17 | — | — | US | disclosed |
| WO-2005056015-A1 | SUBSTITUTED PIPERAZINES | CHEMOCENTRYX, INC. (US) | 2005-06-23 | — | — | WO | disclosed |